Cinepazide Maleate2...

Cinepazide Maleate26328-04-1 top quality and Factory direct sales
Cinepazide Maleate26328-04-1 top quality and Factory direct sales

Cinepazide Maleate26328-04-1 top quality and Factory direct sales

Min.Order / FOB Price:Get Latest Price

100 Gram

Negotiable

  • Min.Order :100 Gram
  • Purity: 99%
  • Payment Terms : T/T,

Keywords

Cinepazide Maleate 26328-04-1 top quality and Factory direct sales

Quick Details

  • Appearance:White crystalline powder
  • Application:1. Cerebrovascular diseases: cerebral arteriosclerosis, transient cerebral ischemia, cerebral thrombosis, cerebral embolism, cerebral hemorrhage and sequelae of brain trauma. 2. Cardiovascular disease
  • PackAge:100g/ bag, 2 kg/ bag, 25kg/ carton or as required
  • ProductionCapacity:20000|Kilogram|Day
  • Storage:Store in sealed containers at cool & dry place. Protect from light, moisture and pest infestation.
  • Transportation:By DHL, TNT, FedEx, HKEMS, UPS, Etc

Superiority:

1. Guaranteed purity;

2. Large quantity in stock;

3. Largest manufacturer;

4. Best service after shipment with email;

5. High quality & competitive price;

 

 

Details:

Cinepazide Maleate
CAS: 26328-04-1
English name Cinepazide maleate
Alias: 1-[(1-Pyrrolidinylcarbonyl) methyl]-4-(3,4,5-trimethoxycinnamoyl) piperazine maleate
Name: Cinepazide Maleate; 1-[(1-pyrrolidine formyl) methyl]-4-(3,4,5-trimethoxycinnamoyl) piperazine maleate
Appearance: White crystalline powder
Content: > 99%
Molecular structure:
Molecular weight: 533.57
Melting point: 170 ~175 C
PH: 3.0-4.0
Drying Weightlessness: <0.5%
Heavy metals: <10 ppm
Packaging: 1kg/listen
Molecular formula: C22H31N3O5.C4H4O4
Molecular weight: 533.57
Usage 1. Cerebrovascular diseases: cerebral arteriosclerosis, transient cerebral ischemia, cerebral thrombosis, cerebral embolism, cerebral hemorrhage and sequelae of brain trauma. 2. Cardiovascular diseases, for atherosclerosis, angina pectoris, patients with myocardial infarction should cooperate with the relevant drug treatment. 3. Fundus vascular diseases, cochlear vestibular dysfunction caused by ischemia, sudden deafness and tinnitus. 4. Microcirculation disturbance caused by diabetes mellitus (diabetic foot, diabetic retinopathy, etc.). 5. Other peripheral vascular diseases: thromboangiitis obliterans, arteritis, Reynolds disease, lower extremity atherosclerosis, etc.
Chinese Name Cinepazide Maleate
The English name Cinepazide Maleate
Chinese alias 1-[(1-pyrrolidine formyl) methyl]-4-(3,4,5-trimethoxycinnamoyl) piperazine maleate
CAS RN 26328-04-1
EINECS 247-613-1
Molecular formula C26H33N3O9
Molecular weight 531.556
English name: Cinepazide maleate
Chemical name: 1-[(1-pyrrolidine formyl) methyl]-4-(3,4,5-trimethoxycinnamoyl) piperazine maleate
1-[(1-Pyrrolidinylcarbonyl) methyl]-4-(3,4,5-trimethoxycinnamoyl) piperazine maleate
Molecular formula: C22H31N3O5. C4H4O4
Molecular weight: 533.58
CAS No. 26328-04-1
Appearance: White crystalline powder
Melting Point: 173-174 degrees C
Content: > 99%
Purpose: Cerebral vascular disease, cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral embolism, post-operative recovery period of brain injury, sequelae of cerebral hemorrhage and sequelae of brain injury; Cardiovascular disease for coronary heart disease, angina pectoris, such as myocardial infarction, should be combined with relevant drugs; Atherosclerosis, thromboangiitis obliterans, arteritis, Reynolds disease; ophthalmology, otorhinolaryngology diseases, fundus vascular sclerosis, obstruction, ischemia caused by eye diseases, ischemia caused by cochlear vestibular dysfunction, sudden deafness, tinnitus, etc; diabetes caused by peripheral vascular lesions and microcirculation disorders

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View